Werewolf Therapeutics
HOWL
42 hedge funds and large institutions have $326M invested in Werewolf Therapeutics in 2021 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 15 increasing their positions, 12 reducing their positions, and 5 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 12
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
2.72% less ownership
Funds ownership: 71.67% → 68.94% (-2.7%)
5% less capital invested
Capital invested by funds: $344M → $326M (-$18M)
7% less funds holding
Funds holding: 45 → 42 (-3)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Russell Investments Group
London,
United Kingdom
|
+$2.15M |
| 2 |
CCM
CAAS Capital Management
New York
|
+$1.07M |
| 3 |
State Street
Boston,
Massachusetts
|
+$645K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$483K |
| 5 |
LCS
Levin Capital Strategies
New York
|
+$256K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$13.7M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.31M |
| 3 |
Goldman Sachs
New York
|
-$653K |
| 4 |
AC
Aristides Capital
Louisville,
Kentucky
|
-$446K |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$429K |
HOWL Hedge Fund Activity: Q3 2021 in Review
42 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Werewolf Therapeutics (HOWL) for Q3 2021, worth a combined $326M — down 5.2% from $344M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of HOWL and 2 opened new positions — a net loss of 3 holders — while 12 trimmed existing stakes and 15 added.
The largest buyer was Russell Investments Group, opening a new position worth an estimated $2.15M. The largest seller was Deerfield Management, cutting an estimated $13.7M.
- 42 institutional investors held Werewolf Therapeutics (HOWL) as of Q3 2021, down from 45 in Q2 2021.
- Funds reported $326M of Werewolf Therapeutics stock for Q3 2021, down 5.2% quarter-over-quarter.
- 2 funds opened new Werewolf Therapeutics positions in Q3 2021 and 5 closed out, a net change of -3 holders.
- The largest Werewolf Therapeutics buyer in Q3 2021 was Russell Investments Group, an estimated $2.15M added.
- The largest Werewolf Therapeutics seller in Q3 2021 was Deerfield Management, an estimated $13.7M sold.
Based on aggregated 13F filings for Q3 2021.